Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Abiomed, Inc.    ABMD


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abiomed : Announces Q2 FY 2021 Revenue of $210 Million, Up 27% over Q1 FY 2021 and Up 2% over Q2 FY 2020 With 29.2% Operating Margin

10/30/2020 | 09:45am EST

DANVERS - Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported second quarter fiscal 2021 revenue of $209.8 million, a sequential increase of 27% compared to Q1 fiscal year 2021 and a year over year increase of 2% compared to Q2 fiscal year 2020 despite the negative impact of COVID-19.

Operating income was $61.3 million up 2%, compared to $60.2 million in the same period of fiscal 2020.

Recent financial and operating highlights include: Worldwide Impella heart pump revenue for the quarter totaled $199.7 million, a sequential increase of 29% compared to revenue of $155.4 million during Q1 fiscal year 2021 and a 1% increase compared to revenue of $196.9 million during Q2 fiscal year 2020.

U.S. Impella product revenue for the quarter totaled $163.2 million, a sequential increase of 29% compared to revenue of $126.2 million during Q1 fiscal year 2021 and a decrease of 1% compared to revenue of $164.7 million during Q2 fiscal year 2020 with U.S. patient usage of the Impella heart pumps up 24% over prior fiscal quarter and down 4% over prior fiscal year.

Outside the U.S., Impella product revenue for the quarter totaled $36.5 million, a sequential increase of 25% compared to revenue of $29.2 million during Q1 fiscal year 2021 and an increase of 13% compared to revenue of $32.2 million during Q2 fiscal year 2020. European Impella product revenue increased 29% compared to the prior fiscal quarter and 16% compared to the prior fiscal year. Japan Impella product revenue increased 14% compared to the prior fiscal quarter and 5% compared to the prior fiscal year.

Gross margin for the second quarter fiscal 2021 was 81.5% compared to 83.0% during the same period of fiscal 2020.

Operating income for the second quarter fiscal 2021 was $61.3 million, or 29.2% operating margin, compared to $60.2 million, or 29.4% operating margin in the same period of fiscal 2020.

Second quarter fiscal 2021 GAAP net income was $62.2 million, or $1.36 per diluted share, which includes a $8.2 million, or $0.18 per diluted share, gain on our investment in Shockwave and a $7.9 million, or $0.17 per diluted share, of excess tax benefits related to employee share-based compensation awards. This compared to GAAP net income of $13.1 million or $0.28 per diluted share for the prior fiscal year.

The company generated operating cash flow of $77.2 million in the second quarter. As of September 30, 2020, the company had $735.7 million of cash and marketable securities and no debt.

At the end of second quarter fiscal 2021, Abiomed has 929 patents and 835 patents pending due to our continued innovation and expanding our global reach.

In October, at TCT Connect, more than 20 presentations and abstracts were presented validating the benefits of a more complete revascularization with Impella heart pumps in high-risk percutaneous coronary intervention (PCI) patients and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock and right heart failure patients. Key data presented includes:

New PROTECT III study data demonstrates reduced rates of MACCE (composite of death, stroke, myocardial infarction and repeat procedures) compared to the Protect II dataset (15% vs. 21.9%, p=0.035).

The Restore EF Study demonstrates the use of contemporary best practices with Impella-supported high-risk PCI enables a more complete revascularization and is associated with significant improvement of left ventricular ejection fraction (45% relative improvement), heart failure symptoms (80% reduction in NYHA Class III, IV), and anginal symptoms at follow up (99% reduction in CCS Angina Class III, IV).

Data from the RECOVER III post-market approval (PMA) study of AMI cardiogenic shock (AMICS) patients was presented in two studies. The first study, presented by Hemindermeet Singh, MD, of Ascension St. John Hospital, found an 18% relative improvement in overall survival in the recent cohort (2017 - 2019) versus a pre-PMA cohort (2008 - 2014), indicating increased adoption of the cardiogenic shock best practices, including placing Impella pre-PCI has led to an improvement in overall survival rates. The second study, presented by Tayyab Shah, MD, of the Yale School of Medicine, found that placing Impella pre-PCI in AMICS patients is associated with higher survival, particularly in women, as compared to post-PCI (74% relative survival benefit).

Two Impella RP studies find that early identification of right heart failure and early use of Impella RP is associated with significantly higher survival rates. The ongoing PMA post-approval study, RECOVER RIGHT, presented by Mark Anderson, MD, found patients who received Impella RP support within 48 hours of cardiogenic shock onset had a significantly higher survival rate than those who received delayed right-heart support (73% vs. 14%, p

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ABIOMED, INC.
01/14ABIOMED : Third Quarter Fiscal 2021 Earnings and Conference Call Notification
01/07ABIOMED : Continues to Strengthen its Intellectual Property, Now Holds More Than..
01/06Artificial heartmaker Carmat to start sales after EU approval
01/01ABIOMED : Significant Insider Selling in Shares of Abiomed (ABMD) Continues
2020INSIDER TRENDS : Abiomed Insider Extends 90-Day Selling Trend
2020Stocks End Lower After Push for Higher Stimulus Payments Stalls in Senate
2020ABIOMED : to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020ABIOMED : ABMD) sees Significant Insider Selling Continuing
2020INSIDER TRENDS : Selling By Insiders Endures at Abiomed
2020ABIOMED : First Patients, Including a COVID-19 Patient, Treated with Abiomed's I..
More news
Financials (USD)
Sales 2021 834 M - -
Net income 2021 207 M - -
Net cash 2021 608 M - -
P/E ratio 2021 76,6x
Yield 2021 -
Capitalization 15 722 M 15 722 M -
EV / Sales 2021 18,1x
EV / Sales 2022 14,8x
Nbr of Employees 1 536
Free-Float 92,2%
Duration : Period :
Abiomed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIOMED, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 326,60 $
Last Close Price 347,90 $
Spread / Highest target 7,79%
Spread / Average Target -6,12%
Spread / Lowest Target -31,6%
EPS Revisions
Managers and Directors
Michael R. Minogue Chairman, President & Chief Executive Officer
David M. Weber Chief Operating Officer & Senior Vice President
Todd A. Trapp Chief Financial Officer & Vice President
Thorsten Sieß Chief Technology Officer & Vice President
Charles A. Simonton Chief Medical Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ABIOMED, INC.7.51%15 722
ILLUMINA, INC.9.80%59 313